Avant Diagnostics, Inc 3
3 · OncBioMune Pharmaceuticals, Inc · Filed Jun 15, 2020
Insider Transaction Report
Form 3
Avant Diagnostics, Inc
10% Owner
Holdings
Series D-1 Convertible Preferred Stock
→ Common Stock, par value $.0001 per share
Footnotes (1)
- [F1]The Reporting Person owns 1,000 shares of Series D-1 Convertible Preferred Stock which were acquired on June 5, 2020 as consideration for the sale of substantially all of the assets of the Reporting Person to the Issuer (the "Asset Sale"). The shares of Series D-1 Convertible Preferred Stock have no expiration date and shall automatically convert into 54.55% of the Issuer's fully diluted shares of common stock after giving effect to the transactions contemplated by the Asset Sale upon the effectiveness of an amendment to the Issuer's articles of incorporation to increase its authorized shares of common stock, which based on information included in the Issuer's Current Report on Form 8-K filed with the SEC on June 11, 2020, is expected to be approximately 4,441,400,000 shares, or approximately 99% of the Issuer's voting capital stock. The Series D-1 Convertible Preferred Stock votes on an as-converted basis with the Issuer's common stock prior to its conversion.